In a biotech M&A desert, investors go crazy for any sign of water.
That makes it tempting to dismiss the burst of M&A speculation around Sarepta Therapeutics Inc. that erupted on Friday. The company announced CEO Ed Kaye’s planned departure in September, which spurred rumors of a possible buyout, pushing Sarepta shares up as much as 13 percent.
